Best tirzepatide 15 mg and 10mg Peptides GMP Factory

Tirzepatide

Tirzepatide

Other names: Tirzepatide raw powder, Mounjaro, LY-3298176, CHEBI:194186, 

Tirzepatide’s weight loss efficacy is supported by clinical trials. In the SURMOUNT-1 and SURMOUNT-2 trials, participants experienced substantial weight loss, with those on the 15mg dose achieving an average of 13.4% reduction in body weight. Moreover, a higher percentage of individuals taking Tirzepatide reached clinically significant weight loss milestones compared to the placebo group.

Production capacity: Provide customization

Large Factory Professional Manufacturers & Factory

Production Carried OUT Under CGMP Regulation and Trackable

ISO9001 & ISO14000

Get a Bulk quotation

If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.

Tirzepatide Peptide dosage calculator

Referenced Citations

[1]Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1  Investigators.”Tirzepatide Once Weekly for the Treatment of Obesity.”N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.PMID: 35658024

[2]Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators.”Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.”N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.PMID: 34170647

[3]Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT.”Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.”Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27.PMID: 34186022

[4]Syed YY.”Tirzepatide: First Approval.”Drugs. 2022 Jul;82(11):1213-1220. doi: 10.1007/s40265-022-01746-8.PMID: 35830001

[5]Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E.”Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.”Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17.PMID: 35579691

[6]Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA.”Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.”J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396. doi: 10.1210/clinem/dgaa863.PMID: 33236115

[7]Min T, Bain SC.”The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.”Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15.PMID: 33325008

[8]Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á.”Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.”JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078.PMID: 35133415

[9]Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators.”Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.”Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18.PMID: 34672967

[10]Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V.”Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.”Molecules. 2022 Jul 5;27(13):4315. doi: 10.3390/molecules27134315.PMID: 35807558

[11]Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D’Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW.”Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.”JCI Insight. 2020 Sep 3;5(17):e140532. doi: 10.1172/jci.insight.140532.PMID: 32730231

[12]Nauck MA, D’Alessio DA.”Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.”Cardiovasc Diabetol. 2022 Sep 1;21(1):169. doi: 10.1186/s12933-022-01604-7.PMID: 36050763

[13]Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S.”Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.”Nat Med. 2022 Mar;28(3):591-598. doi: 10.1038/s41591-022-01707-4. Epub 2022 Feb 24.PMID: 35210595

[14]Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G.”Tirzepatide: A Systematic Update.”Int J Mol Sci. 2022 Nov 23;23(23):14631. doi: 10.3390/ijms232314631.PMID: 36498958

[15]Farzam K, Patel P.”Tirzepatide.”2023 May 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.PMID: 36251836

[16].What You Need to Know About Reconstituting Tirzepatide Peptide Step By Step

Author of this article:

Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

1.Prof W Timothy Garvey MD

UAB Diabetes Research Center, University of Alabama at Birmingham, Birmingham, AL, USA 

2.Sidar Copur

Department of Medicine, Koc University School of Medicine, Istanbul 34010, Turkey

3.Lyse Bordier

Hôpital Bégin, service d’endocrinologie, Saint-Mandé, France

4.Hikmat Permana

Division of Endocrinology and Metabolic Disorders, Department of Internal Medicine, Padjadjaran University, Bandung, West Java, 45363, Indonesia

5.Akira Mima

Corresponding author. Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, 569-8686, Japan.

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. peptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Author of this article:

Dr. Jean Zeng graduated from king's college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

Stephen C. Bain
Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK
Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.